New Experimental COVID-19 Pill “Molnupiravir” Reduces Hospitalizations, Deaths By Half; Same Manufacturer of “Ivermectin”

Molnupiravir
The creator of Molnupiravir is the same company that manufactured the highly controversial Ivermectin used to treat parasitic infections for three hundred million people. Early in the pandemic Ivermectin was thought to help treat COVID-19 however, current data is deemed inconclusive.

KENILWORTH, NJ – On Friday, multinational pharmaceutical company Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that an experimental COVID-19 pill they are working on has cut the number of study cases leading to hospitalization or death by half, and that they have plans to submit the new medication to the Food and Drug Administration (FDA) – as well as other health officials worldwide – for evaluation and authorization for wide use.

Merck & Co. – which is headquartered in Kenilworth, New Jersey – would be the first-ever company to manufacture a pill to combat COVID-19 if it is approved by the FDA; currently, all treatments consist of injections or via an IV.

Molnupiravir (MK-4482, EIDD-2801), – developed by Merck in partnership with Ridgeback Biotherapeutics – is said to have halved the number of both hospitalizations and deaths from COVID-19 in patients who were administered the pill within five days of showing symptoms of infection by the virus.

According to Merck, the study was conducted among 775 adults infected with mild-to-moderate cases of COVID-19 and who had underlying health problems that made them more susceptible to the illness, such as being overweight or suffering from diabetes or heart conditions. 7.3 percent of the patients in the study who took molnupiravir had been hospitalized or died within a 30 span of time; for recipients of a placebo pill, that number increased to 14.1 percent within the same time period.


FREE DIGITAL SUBSCRIPTION: GET ONLY 'FEATURED' STORIES BY EMAIL

Big Tech is using a content filtering system for online censorship. Watch our short video about NewsGuard to learn how they control the narrative for the Lamestream Media and help keep you in the dark. NewsGuard works with Big-Tech to make it harder for you to find certain content they feel is 'missing context' or stories their editors deem "not in your best interest" - regardless of whether they are true and/or factually accurate. They also work with payment processors and ad-networks to cut off revenue streams to publications they rate poorly by their same bias standards. This should be criminal in America. You can bypass this third-world nonsense by signing up for featured stories by email and get the good stuff delivered right to your inbox.
 

After the 30 days had elapsed, no additional patients who had taken molnupiravir passed away, as opposed to eight deaths in the placebo group, Merck officials say, some side effects were suffered by individuals in both groups. The pill, however, was not effective among those who had “severe” COVID-19 cases, they said.

Merck’s results have yet to be officially released to the public, but the company has noted it will do so at a medical meeting in the near future – in addition to plans to submit data to the FDA for review – with Vice President of Merck research Dr. Dean Li saying that he was very impressed by molnupiravir’s performance thus far.

“It exceeded what I thought the drug might be able to do in this clinical trial,” he said. “When you see a 50 percent reduction in hospitalization or death that’s a substantial clinical impact.”

Merck is the same pharmaceutical company that manufactured the highly controversial ivermectin which has been used to treat parasitic infections such as river blindness and lymphatic filariasis for three hundred million people in more than 30 countries. Early in the pandemic Ivermectin was thought to help treat COVID-19 however, current evidence on the use of ivermectin for COVID-19 patients is deemed inconclusive.


Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to corrections@publishedreporter.com and cite any sources if available. Thank you. (Policy)